New Irish Generics Body Wants “Fundamental” Reform Of Medicines Procurement
Two generic industry associations have merged to form a single body that includes the largest generic companies in Ireland. Medicines For Ireland has marked its creation by saying it plans to push for a reform of Irish medicines procurement policies, particularly in areas such as tackling drug shortages, and has called for action to promote the use of biosimilars.
You may also be interested in...
The Irish health ministry is planning measures to boost the prescribing of biosimilar medicines, but companies marketing biosimilars say that the pricing agreement signed last year by the originator industry and the government has served to hinder uptake of their products.
The Association of Pharmaceutical Manufacturers in Ireland (APMI) has been relaunched as the Irish Generic Medicines Association (IGMA), a name that is designed to reflect its specific remit, scope of functions and responsibilities, it announced. The association represents seven companies employing 2,300+ people in Ireland. The member companies are Accord Healthcare, Actavis Ireland, Clonmel Healthcare Ltd, Fannin Ltd, Hospira Ireland, Rowex Ltd and Pinewood Healthcare. The organization's primary purpose is to promote and support the supply of affordable medicines in Ireland, and is the recognized negotiating body on supply and pricing of generics in the country. Among other things, it is calling for new legislation in Ireland on biosimilars and high-tech generic molecules.
As discussions continue over the European Commission’s plans to overhaul the EU pharmaceutical legislation, the R&D-based pharma industry body EFPIA says that any new pharma policy framework will need to be stable, fast, effective and globally competitive.